Loading…
Employees: 641
Size Gansu Longshenrongfa Pharmaceutical Industry (300534.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $450M, the 4110th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥9.88 on 6 Nov 2026.
Performance Over six months the shares gained 4.3%, against -18.1% for the median peer and -16.4% for the China market (cap-weighted) — 4th highest of 19 in its peer set.
Growth Revenue fell 21.0% over the last twelve months (peer median +5.5%); the operating margin is 8.5% (peer median 4.0%).
Valuation It trades at 4.3× enterprise value to sales against a peer median of 3.6× (10th most expensive of 20).
Price implies For today's price to make sense, revenue must grow about 24% a year for seven years (Req g). Recent delivered growth is +28%, so the hurdle is -4 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 0.5 points below its cost of capital (9.2% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥695M | CN¥878M | CN¥1.03B | CN¥1.07B | CN¥793M |
| Revenue growth | — | -15% | -4% | +35% | — |
| Gross profit | CN¥493M | CN¥584M | CN¥730M | CN¥674M | CN¥441M |
| EBITDA | n/a | CN¥132M | CN¥133M | CN¥112M | CN¥78.2M |
| Net income | CN¥19.9M | CN¥44.0M | CN¥24.5M | CN¥61.6M | CN¥38.8M |
| Free cash flow | CN¥65.3M | -CN¥49.1M | CN¥138M | -CN¥29.8M | CN¥243M |
| Capital expenditure | CN¥27.7M | CN¥43.4M | CN¥77.7M | CN¥126M | CN¥25.4M |
| Total debt | CN¥139M | CN¥156M | CN¥138M | CN¥145M | CN¥0 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300534.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -19.1% | -11.7% | 6th lowest of 20 |
| 6-month return | +4.3% | -18.1% | 4th highest of 19 |
| Distance from 52-week high | -52.9% | -40.7% | 4th lowest of 20 |
| Revenue growth (TTM) | -21.0% | +5.5% | 2nd lowest of 20 |
| Operating margin | 8.5% | 4.0% | 8th highest of 20 |
| EV / Sales | 4.3× | 3.6× | 10th most expensive of 20 |
| Growth the price implies (Req g, 7 yrs) | 23.7% | 14.8% | 4th most demanding of 9 |
| Growth delivered (Del g) | +28.2% | +2.4% | highest of 9 |
| Hurdle (Req g minus delivered) | -4.5 pp | +11.0 pp | 2nd least demanding of 9 |
| ROIC minus cost of capital | -0.5 pp | -2.2 pp | 9th highest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Gansu Longshenrongfa Pharmaceutical Industry 300534.SZ | China | $450M | +4% | -21% | 8% | 4.3× | 23.7% | +28.2% |
| Evolus EOLS | United States | $449M | +7% | +14% | -7% | 1.8× | n/a | n/a |
| Shanghai Fudan Forward S&T 600624.SS | China | $450M | -4% | -14% | -34% | 6.0× | n/a | n/a |
| RPG Life Sciences RPGLIFE.NS | India | $448M | +2% | +12% | 18% | 5.8× | n/a | n/a |
| Aquestive Therapeutics AQST | United States | $454M | -16% | +13% | -114% | 10.5× | n/a | n/a |
| Gufic Biosciences GUFICBIO.NS | India | $454M | +44% | +17% | 14% | 4.4× | n/a | n/a |
| Beijing Foyou Pharma 601089.SS | China | $455M | -24% | +5% | 10% | 0.2× | n/a | n/a |
| Synmosa Biopharma 4114.TWO | Taiwan | $442M | +2% | +11% | 11% | 2.5× | 6.5% | +15.3% |
| Zhejiang Chengyi Pharmaceutical 603811.SS | China | $463M | -21% | +7% | 19% | 3.6× | 7.1% | +1.3% |
| Zhuhai Rundu Pharmaceutical 002923.SZ | China | $464M | -30% | +14% | 5% | 2.4× | 2.5% | -1.3% |
| Shanghai Jiaoda Onlly 600530.SS | China | $464M | -22% | -2% | -2% | 10.4× | 33.5% | -0.9% |
| Teyi Pharmaceutical 002728.SZ | China | $465M | -9% | -7% | 7% | 3.5× | 26.6% | +8.0% |
| Shaanxi Kanghui Pharmaceutical Co 603139.SS | China | $466M | -20% | -21% | -68% | 9.0× | n/a | n/a |
| Evonile Pharma EVONILE.NS | India | $466M | n/a | -5% | 12% | 14.5× | 46.5% | -1.5% |
| Harbin Medisan Pharmaceutical 002900.SZ | China | $467M | -13% | -5% | -29% | 4.5× | n/a | n/a |
| Jiangsu Bioperfectus Technologies 688399.SS | China | $432M | -44% | -8% | -23% | 5.7× | n/a | n/a |
| Aarti Drugs AARTIDRUGS.NS | India | $430M | +12% | +15% | 11% | 1.6× | 19.7% | +3.5% |
| Beijing Centergate Technologies (Holding) 000931.SZ | China | $430M | -20% | -16% | 2% | 2.0× | 9.9% | +6.7% |
| Zhejiang Huakang Pharmaceutical 605077.SS | China | $470M | -39% | +35% | 4% | 1.2× | n/a | n/a |
| Kexing Biopharm 688136.SS | China | $470M | -38% | -14% | -12% | 3.1× | n/a | n/a |
| BlossomHill Therapeutics BLSM | United States | $429M | n/a | n/a | n/a | n/a | n/a | n/a |